BRAIN BIOTECNA O.N. news, videos and press releases
For more news please use our advanced search feature.
BRAIN BIOTECNA O.N. - More news...
BRAIN BIOTECNA O.N. - More news...
- EQS-News: Annual Report 2023/24: BRAIN Biotech AG acts from a strong cash position and is confident about its growth prospects
- EQS-News: BRAIN Biotech AG Sharpens Focus on Profitable Growth
- EQS-News: BRAIN Biotech AG and Akribion Therapeutics GmbH sign exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology
- EQS-Adhoc: BRAIN Biotech AG signs exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology with Akribion Therapeutics GmbH for up to EUR 92.3 million milestone fees plus royalties
- EQS-News: Prof. Dr. Wiltrud Treffenfeldt leaves Supervisory Board of BRAIN Biotech AG for personal reasons
- EQS-News: BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator
- EQS-Adhoc: BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma
- EQS-News: BRAIN Biotech AG presents strong cash position with its 9M reporting and is forecasting good sequential growth in the final quarter of the business year
- EQS-News: BRAIN Biotech AG announces the appointment of Erik de Vries as Senior Business Development Director Enzymes
- EQS-News: BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets
- EQS-News: BRAIN Biotech AG takes next step to optimize group structure
- EQS-News: Beverages made from vine leaves: Sustainable drinking pleasure based on agricultural side streams
- EQS-News: Results of the Annual General Meeting 2024 for the financial year 2022/23 of BRAIN Biotech AG
- EQS-News: Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials
- EQS-News: BRAIN Biotech AG successfully placed EUR 5.0 million convertible bond for the financing of further growth initiatives
- EQS-Adhoc: BRAIN Biotech AG: Issuance of EUR 5 million convertible bond with exclusion of subscription rights
- EQS-News: 3M FY 23/24: BRAIN Biotech looks optimistic to stay on the growth path for fiscal year 2023/24
- EQS-News: Annual Report 2022/23: BRAIN Biotech AG successfully executes growth strategy
- EQS-News: Akribion Genomics receives the Hessian Founder Award for its innovative approach to a new cancer therapy
- EQS-News: BRAIN Biotech AG: BRAIN Biotech AG´s Akribion Genomics team wins first prize at the “BioRiver Boost!” startup competition
- EQS-News: BRAIN Biotech AG: BRAIN Biotech AG’s Akribion Genomics technology receives patent approval for its groundbreaking nuclease G-dase E®
- EQS-News: BRAIN Biotech AG: Scientist from BRAIN Biotech AG receives VAAM Innovation Award for the discovery of a novel CRISPR nuclease family
- EQS-News: BRAIN Biotech AG reports solid 9M numbers despite ongoing high R&D investments and more challenging economic conditions
- EQS-News: BRAIN Biotech AG´s Akribion Genomics team successfully competes in Science4Life Venture Cup competition
- EQS-News: Anniversary of BRAIN Biotech AG: 30 years for a bio-based future
- EQS-News: BRAIN Biotech AG stays on solid growth path with H1 results and accelerates One-BioProducts strategy
- EQS-News: BRAIN Biotech AG gains full ownership of Biocatalysts Ltd and accelerates execution of its One-BioProducts Strategy
- EQS-News: Resolutions of the Annual General Meeting 2023 on the Financial Year 2021/2022 of BRAIN Biotech AG
- EQS-News: Capital Markets Day 2023: BRAIN Biotech AG to build an international multi-niche enzyme and food ingredients champion
- EQS-News: BRAIN Biotech AG with Strong Start into Fiscal Year 2022/23, 3M Reporting
